Curie.Bio is a unique combination of two businesses: we act as both your drug discovery copilot & seed investor. We have some of the world’s best drug hunters, drug makers, experts, and vendors supporting our founders to increase their chances of developing successful medicines.
By support, we don’t mean just a couple of hours a month. We are in the trenches with you on a day-to-day basis operating as fully integrated members of your team. We help you choose therapeutic targets, set milestones based on investor feedback, and design experimental plans. We interview and select drug discovery vendors to enable you to hit those milestones. We help identify what expertise needs to be brought in to support your key programs and then get you the right experts. We evaluate incremental data readouts with you to help determine which experiments need to be adjusted from the initial plan. We do real work.
When you’re ready for your Series A, we work with you end-to-end on your data room, deck, and pitch. We make investor intros and coach you on how to run an excellent fundraising process to optimize the quality of your round.
Curie.Bio’s model gives you a higher chance of success & reduces future dilution. How?
- By working with us, you make significant progress on your lead program(s) while being extremely capital efficient. We provide real help designing and executing your seed plan, including navigating the bumps, twists, and turns all along the way.
- This progress leads to better terms when raising a Series A & Series B. Investors now have a clear line of sight to getting your lead program(s) into the clinic.
- Post Curie.Bio’s seed, founders are positioned to raise significant capital to advance their programs without giving up as much future equity in their company.
Simply put: better planning and more progress at the seed means a significantly higher chance of a future where you retain control, upside, and agency over your own company.
Why us?
- Our team has brought over 60 drugs into the clinic with 12 approvals.
- Our team has founded biotech companies with more than $30 billion in enterprise value.
- We aim to bring our decades of experience to founders across the globe and have raised over $500m to make our vision a reality.
We started with a problem statement: you can’t start a therapeutics company in your garage. Drug discovery is an incredibly complex process with multiple points of failure, particularly in the earliest stages of building a new company.
We’re launching with a big idea: if we can help founders avoid mistakes, ensure they have the right data, plan & story, all while retaining the incentive to build their own company, we could in essence, free the founders.
We believe the single greatest unlock of innovation in biotech over the next decade will come from creating more founders – more risk takers – more scientists with phenomenal ideas who have the support they need to start their own company.